Should UnitedHealth Stock Investors Worry About Its Third Quarter?
For questions about this article or underlying research, email help@trefis.com.
UnitedHealth Group (UNH) generated $113 billion of revenue in the third quarter of 2026, a 0.4% decline from a year earlier. That small dip is the number a holder should worry about. Management has set a long-term earnings growth target of 13% to 16%. With flat sales, that growth will likely have to come mostly from wider margins. Is the dip one soft quarter, or has UnitedHealth’s growth been fading all year?
UnitedHealth Saw Sales Growth Slow Each Quarter Of 2026
The third-quarter dip is the latest step in a slide that ran throughout the entire year. UnitedHealth’s revenue grew 12.3% from a year earlier in the fourth quarter of 2025. Growth then slowed to 2.0% in the first quarter of 2026, and by the second quarter it was barely positive at 0.4%.
The company is roughly holding its size: quarterly revenue has stayed between $112 billion and $113 billion in each of the last four quarters. But over the twelve months to September 2026, revenue grew 3.3%, against 10.5% in the twelve months before, so the slowdown shows up in the wider view too.
What Are UnitedHealth Shareholders Paying For?
UnitedHealth shareholders are paying 22.5 times the last twelve months’ earnings at the November 9 close, slightly more than the 21.8 times for the S&P 500. The shares have returned 26.9% over the past year, against 13.7% for the index, and that price likely assumes the earnings growth management is targeting.
On its October 13 call, management said it expects 2026 adjusted earnings per share of at least $20.50. It said current analyst consensus for 2027 may understate the opportunity ahead, and it called the low end of its long-term target a more reasonable starting point for 2027. Growth of 13% from that base would mean about $23.17 of adjusted earnings per share in 2027.
Management also named the pressure on its margins. Cost growth in its commercial business is running above 11%, higher than the company first expected, driven by costs tied to the No Surprises Act, clinicians and high-cost specialty drugs. Management said those pressures will stretch out its ability to reach its long-term margins in the commercial business.
The risk for a holder is that the shares can fall hard: the stock has fallen much harder than the market at least once before. In the 2025 tariff shock, between February and June 2025, it lost 46% from peak to trough, against 19% for the S&P 500 ETF.
UnitedHealth Earned More On Flat Third-Quarter Sales
UnitedHealth’s operating margin rose to 5.8% in the third quarter of 2026, from 3.8% a year earlier, on revenue that did not grow. Its operating margin for the twelve months to September 2026 was 5.3%, still below 6.1% a year before and 8.2% two years before. Management also said it now expects its Medicare margin for 2026 to land near the top of its 2% to 4% range, and it credited recovery actions taken during the year. That is the kind of margin-led growth the share price likely assumes, and UnitedHealth delivered some of it in the third quarter.
A holder should be moderately worried. UnitedHealth’s sales have stopped growing while its shares cost slightly more than the S&P 500 on earnings, although its margin widened in the third quarter. Management plans to give a fuller outlook for 2027 before the end of 2026, and the company is expected to report again in January 2027. Revenue growth against a year earlier is the number to watch in that report.
Want Income That Doesn’t Hang On One Company?
Every single stock carries risks like these. The Trefis Income Solution spreads your money across 50 dividend stocks, each with at least 10 straight years of dividends, with a yield about 3x the S&P 500.
Spot an error or want more like this? Tell us in 10 seconds.